We are live on ! Find out more
ALBO

Albireo Pharma Inc
ALBO

Delisted

ALBO was delisted on the 2nd of March, 2023.

Back to rankings

37 hedge funds and large institutions have $11.6M invested in Albireo Pharma Inc in 2014 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 9 increasing their positions, 8 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

13% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 8

14% less funds holding

Funds holding: 43 → 37 (-6)

35% less capital invested

Capital invested by funds: $17.8M → $11.6M (-$6.2M)

55% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 11

67% less call options, than puts

Call options by funds: $38K | Put options by funds: $116K

Holders
37
Holders Change
-6
Holders Change %
-13.95%
% of All Funds
1.06%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
9
Reduced
8
Closed
11
Calls
$38K
Puts
$116K
Net Calls
-$78K
Net Calls Change
+$256K

Top Buyers

Rank Fund Capital Flow
1
Wellington Management Group
Wellington Management Group
Massachusetts
+$762K
2
SM
Sabby Management
Florida
+$558K
3
Goldman Sachs
Goldman Sachs
New York
+$254K
4
Renaissance Technologies
Renaissance Technologies
New York
+$94.5K
5
Vanguard Group
Vanguard Group
Pennsylvania
+$21.1K

Top Sellers

Rank Fund Capital Flow
1
William Blair & Company
William Blair & Company
Illinois
-$1.07M
2
NI
Numeric Investors
Massachusetts
-$914K
3
SFM
Sphera Funds Management
Israel
-$775K
4
FNYS
First New York Securities
New York
-$666K
5
TC
TFS Capital
Pennsylvania
-$531K
Name Holding Trade Value Shares
Change 		Change in
Stake
BC
1
Broadfin Capital
New York
$2.87M – – –
Wellington Management Group
2
Wellington Management Group
Massachusetts
$2.34M +$762K +10,962 +44%
William Blair & Company
3
William Blair & Company
Illinois
$1.88M -$1.07M -15,420 -38%
Vanguard Group
4
Vanguard Group
Pennsylvania
$1.07M +$21.1K +304 +2%
SM
5
Sabby Management
Florida
$520K +$558K +8,020 New
Renaissance Technologies
6
Renaissance Technologies
New York
$487K +$94.5K +1,359 +22%
Goldman Sachs
7
Goldman Sachs
New York
$486K +$254K +3,647 +95%
O
8
OrbiMed
New York
$453K -$441K -6,343 -48%
Susquehanna International Group
9
Susquehanna International Group
Pennsylvania
$198K +$8.34K +120 +4%
TC
10
TFS Capital
Pennsylvania
$184K -$531K -7,635 -73%
SKK
11
Shepherd Kaplan Krochuk
Massachusetts
$153K – – –
CC
12
Cannell & Co
New York
$151K – – –
Dimensional Fund Advisors
13
Dimensional Fund Advisors
Texas
$121K – – –
BFA
14
BlackRock Fund Advisors
California
$114K +$3.48K +50 +3%
Geode Capital Management
15
Geode Capital Management
Massachusetts
$95K – – –
D.E. Shaw & Co
16
D.E. Shaw & Co
New York
$54K -$37.6K -541 -39%
Northern Trust
17
Northern Trust
Illinois
$54K -$70 -1 -0.1%
California Public Employees Retirement System
18
California Public Employees Retirement System
California
$49K – – –
RCM
19
Rotella Capital Management
Washington
$48K -$23.2K -334 -31%
FAAS
20
First Allied Advisory Services
California
$43K – – –
RA
21
Royce & Associates
New York
$43K – – –
LTFS
22
Ladenburg Thalmann Financial Services
Florida
$37K – – –
Nomura Holdings
23
Nomura Holdings
Japan
$30K – – –
PAG
24
Private Advisor Group
New Jersey
$28K – – –
Bank of New York Mellon
25
Bank of New York Mellon
New York
$26K +$139 +2 +0.5%
1
2

ALBO Hedge Fund Activity: Q2 2014 in Review

37 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in Albireo Pharma Inc (ALBO) for Q2 2014, worth a combined $11.6M — down 35% from $17.8M a quarter earlier.

Sellers outnumbered buyers: 11 funds closed out of ALBO and 5 opened new positions — a net loss of 6 holders — while 8 trimmed existing stakes and 9 added.

The largest buyer was Wellington Management Group, adding an estimated $762K. The largest seller was William Blair & Company, cutting an estimated $1.07M.

  • 37 institutional investors held Albireo Pharma Inc (ALBO) as of Q2 2014, down from 43 in Q1 2014.
  • Funds reported $11.6M of Albireo Pharma Inc stock for Q2 2014, down 35% quarter-over-quarter.
  • 5 funds opened new Albireo Pharma Inc positions in Q2 2014 and 11 closed out, a net change of -6 holders.
  • The largest Albireo Pharma Inc buyer in Q2 2014 was Wellington Management Group, an estimated $762K added.
  • The largest Albireo Pharma Inc seller in Q2 2014 was William Blair & Company, an estimated $1.07M sold.

Based on aggregated 13F filings for Q2 2014.